drugset / Trial / NCT05142514
Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2)
Phase 2
Completed
629 enrolled
Hipra Scientific, S.L.U
Laboratorios Hipra, S.A. · collabNational Institute of Hygiene and Epidemiology, Vietnam · collab
RandomizedSingle-groupDouble-blindPrevention
Summary
This is a Phase IIb, randomized, controlled, observer-blinded, clinical trial to evaluate safety and immunogenicity of COVID-19 Vaccine HIPRA in adult healthy volunteers in Vietnam
Timeline
- Start
- 2021-11-11
- Primary completion
- 2021-12-27
- Completion
- 2022-05-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | BioNTech - Pfizer COVID-19 vaccine | Messenger RNA (mRNA) | — | — |
| Subject | COVID-19 Vaccine HIPRA | Vaccine | — | — |